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ABSTRACT 
Purpose: Wilson Disease (WD) is an autosomal recessive disorder of copper metabolism, caused by 
mutations in ATP7B. We aimed to: 1) perform a meta-analysis of previous WD prevalence estimates, 
2) estimate the prevalence of WD from population sequencing data, and 3) generate an ATP7B gene 
variant database. 
Methods: MEDLINE and EMBASE were systematically searched. Previous prevalence estimates were 
subjected to meta-analysis. All previously reported pathogenic ATP7B variants were compiled and 
annotated with GnomAD allele frequencies. Pooled global and ethnicity-specific genetic prevalences 
for WD were generated using the Hardy-Weinberg equation.  
Results: Meta-analysis of genetic studies of WD prevalence gave an estimate 12.7 per 100,000 (95% 
CI: 6.3-23.0). We developed a referenced, searchable ATP7B database comprising 11,520 variants 
including 782 previously reported disease variants, which can be found at 
http://www.wilsondisease.tk/. 216/782 of these were present in GnomAD, remained after filtering 
by allele frequency and met American College of Medical Genetics criteria. Based on these, the 
genetic prevalence of WD was 13.9 per 100,000 (95% CI: 12.9-14.9), or 1 per 7,194. Combining this 
with 60 predicted pathogenic variants gave a birth prevalence of 15.4 per 100,000 (95% CI: 14.4-
16.5). 
Conclusion: The genetic prevalence of Wilson disease may be greater than previous estimates.  
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INTRODUCTION 
Wilson Disease (WD) is an autosomal recessive disorder of copper metabolism, in which there is 
defective transport of copper across the endoplasmic reticulum and biliary copper excretion. This 
manifests as hepatic, neurological and psychiatric symptoms. Diagnosis is based on a combination of 
clinical features, serum caeruloplasmin, urinary copper and hepatic copper1, with early detection 
and effective treatment resulting in a normal life-span with minimal morbidity. 
WD is known to be caused by mutations in the ATP7B gene. Although the possibility of a second WD 
gene has been discussed, no other genes have been identified2. Indeed, study sequencing 181 
patients in the UK found an overall ATP7B mutation detection frequency of 98%3, supporting the 
belief that WD is a classic monogenic disorder. However, the mutational spectrum is wide, with the 
WD Mutation Database by the University of Alberta (last updated in 2010) listing around 500 
pathogenic variants 4 though the actual number may be greater. ATP7B mutation testing may be 
required for the diagnosis of WD but it is not yet routine1. 
The prevalence of WD is often quoted as 1 in 30,000, taken from a monograph written by Scheinberg 
and Sternlieb in 1984, before the discovery of the gene responsible5. This estimate was based on 
three studies that have been described as methodologically flawed6 and it has been recognised 
some regions have a much higher prevalence. In accordance with this, recent estimates from 
sequencing studies have been much higher, with several papers raising the possibility of under-
diagnosis3,7,8. Moreover, reports of WD in consecutive generations of families, producing a 
‘pseudodominant’ inheritance pattern, suggest that heterozygous ATP7B mutation carriers may be 
more common than previously thought3. 
Therefore, we aimed to, firstly, perform a meta-analysis of previous prevalence estimates for WD 
and secondly, estimate the prevalence of WD across ethnicities from publicly available population 
sequencing data, using a validated methodology9. In addition, we aimed to compile a new database 
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of reported WD pathogenic variants by systematically searching the literature and cross-referencing 
with pre-existing databases. 
 
MATERIALS AND METHODS 
The protocol for this study was registered with PROSPERO 
(https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=74489) 
 
Meta-analysis of previous prevalence estimates 
Both MEDLINE and EMBASE were systematically searched for papers related to Wilson disease 
prevalence or epidemiology on 15/08/17 (see supplementary data for search terms). Two 
independent reviewers (JG & SB) screened abstracts to determine suitability for inclusion. Any 
disagreement was resolved through discussion with a third reviewer (JM). Foreign language reports; 
reviews, commentaries and editorials reporting non-original data; and in vitro or non-human studies 
were excluded; papers quoting an original estimate of WD prevalence or incidence were included. 
Included papers were quality reviewed and assessed for risk of bias using the Appraisal tool for 
Cross-Sectional Studies (AXIS)10 (Figure S3) and prevalence data was extracted. Where appropriate, 
prevalence was estimated from the number of cases reported in the manuscript and relevant 
population size data obtained from official statistics, as specified in the results. In addition, where 
multiple prevalence estimates over time were given, the most recent figure was taken.  
Studies were subclassified into epidemiological studies, defined as those based on case frequencies 
within a population, and genetic studies, involving sequencing for WD pathogenic variants and 
calculation of mutant allele frequencies.  
The degree of study heterogeneity was investigated by means of the Cochran Q test and its related 
metric I2. Since in all cases there was significant heterogeneity, estimates of prevalence from 
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epidemiological studies and mutant allele frequencies from genetic studies were subjected to meta-
analysis separately using random effects models11. Population size was taken to be the overall 
population of the catchment area for epidemiological studies and sample size for genetic studies. 
Where population size was unclear in the paper, population data for the appropriate year was 
obtained from WorldBank (data.worldbank.org, accessed 14/03/18), unless otherwise specified. 
From the overall mutant allele frequency an estimate of the prevalence of WD at birth was 
calculated using the Hardy Weinberg equation. 
All statistical analysis was performed using the Meta-XL add-in for Microsoft Excel 
(www.epigear.com). Forest plots were generated using DistillerSR Forest Plot Generator from 
Evidence Partners (www.evidencepartners.com) 
 
Identification of reported pathogenic variants and functional variants  
A systematic search was performed to produce a list of all known disease-causing pathogenic 
variants in the ATP7B gene. Both MEDLINE and EMBASE were searched for papers relating to WD 
mutations or genetics on 15/08/17 (see supplementary data for search terms). As above, two 
independent reviewers screened abstracts to determine suitability for inclusion and disagreements 
were resolved through discussion with a third reviewer. Foreign language reports; reviews, 
commentaries and editorials reporting non-original data; and in vitro or non-human studies were 
excluded; papers reporting variants within the ATP7B gene were included. Variants reported as 
disease-causing were extracted. 
The University of Alberta WD database 12 (www.wilsondisease.med.ualberta.ca/references.asp, 
accessed 02/03/18), ClinVar (www.ncbi.nlm.nih.gov/clinvar/, accessed 13/11/17) were screened for 
additional ATP7B variants with published reports of pathogenicity and these were added to our list. 
Variants derived from personal communications and unpublished data were excluded. Compound 
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mutations, defined as more than 1 non-overlapping mutation within the same ATP7B sequence, 
were also excluded.  
A list of all known variants in ATP7B, including polymorphisms, was compiled. All above variants 
were combined with variants from the University of Alberta WD database and ClinVar without 
evidence of pathogenicity and additional variants from Ensembl (www.ensembl.org, accessed 
26/01/18) and GnomAD (gnomad.broadinstitute.org/, accessed 26/01/18).  
 
Annotation of variants with allele frequencies and functional predictions 
Coding sequence nucleotide changes for each variant were identified and converted to Human 
Genome Variation Society (HGVS) format (hg38) using Mutalyzer (https://mutalyzer.nl/). The 
Ensembl Variant Effect Predictor (https://ensembl.org/Tools/VEP) was used to annotate variants 
with mutation consequences and SIFT/PolyPhen in silico predictions of pathogenicity. GnomAD allele 
frequency data was downloaded directly and added to each variant.  
 
Frequency filtering 
All variants with allele frequency data available from the GnomAD dataset were filtered using a 
method proposed by Whiffin et al13. A ‘maximum credible population allele frequency’ was 
calculated based on the equation: 
𝑀𝑎𝑥 𝑐𝑟𝑒𝑑𝑖𝑏𝑙𝑒 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝐴𝐹
=  √𝑝𝑟𝑒𝑣𝑎𝑙𝑒𝑛𝑐𝑒  × 𝑚𝑎𝑥 𝑎𝑙𝑙𝑒𝑙𝑖𝑐 𝑐𝑜𝑛𝑡𝑟𝑖𝑏𝑢𝑡𝑖𝑜𝑛 × √𝑚𝑎𝑥 𝑔𝑒𝑛𝑒𝑡𝑖𝑐 𝑐𝑜𝑛𝑡𝑟𝑖𝑏𝑢𝑡𝑖𝑜𝑛  
×
1
√𝑝𝑒𝑛𝑒𝑡𝑟𝑎𝑛𝑐𝑒
 
Reliable estimates for these parameters were difficult to obtain, so an upper bound for the 
maximum credible AF was calculated. Prevalence was taken from the meta-analysis estimate from 
genetic studies, 1 in 7874, as these studies are most comparable to our current method. Maximum 
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allelic contribution, the maximum proportion of variation within a gene attributable to a single 
allele, was set at 30%, based on a variety of estimates of p.His1069Gln ATP7B variant prevalence in 
WD patients3,8,14,15. Maximum genetic contribution, the maximum proportion of disease attributable 
to variation within a gene, was set at 98% based on Coffey et al3. Lastly, the penetrance used for this 
calculation was selected as 50%, as suggested by the original authors’ methods. This gave a 
‘maximum credible AF’ of 0.473%. 
 
‘Filtering allele frequencies’ were also computed for each variant based on GnomAD allele counts, 
using the R code provided by Whiffin et al. Variants with ‘filtering AFs’ greater than the ‘maximum 
credible AF’ were excluded from further analysis.  
 
Disease variant classification 
Variants reported as pathogenic with allelic frequency data were further screened and classified 
using American College of Medical Genetics (ACMG) criteria16. Variants reported in a peer-reviewed 
journal were labelled with PS4, PP4 and PP5 level evidence and classified as ‘likely pathogenic’ if 
they: 
1) Were associated with at least 2 of the following criteria5: 
x low ceruloplasmin level <20 mg/dl 
x the presence of Kayser-Fleischer rings by slit-lamp examination  
x hepatic copper content of 250 mcg/g dry weight liver tissue  
x 24hr urinary copper >100mcg  
in the presence of hepatic or neurological manifestations consistent with WD 
2) Had a significantly increased prevalence in affected individuals compared with controls 
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Prevalence estimation 
Allele frequencies of relevant variants were extracted from our ATP7B variant database, pooled, and 
estimates of the prevalence of WD at birth were generated using the Hardy-Weinberg equation. 
95% Confidence intervals for these estimates were calculated as Wilson interval scores by the Wilson 
Score method. Graphs were generated using Microsoft Excel (2016) for Windows.  
 
RESULTS 
Previous estimates of prevalence 
1003 abstracts were identified as potentially eligible, of which 20 studies were included. 12/20 (60%) 
of these employed an epidemiological method and 8/20 (40%) used genetic sequencing (Figure S1). 
From these, 22 estimates of prevalence were extracted, from various locations worldwide and 
reporting population prevalences ranging from 0.25-6667/100,000 (Table 1 and Table 2). Three 
epidemiological studies were excluded from meta-analysis: Dedoussis et al (2005) and Garcia-
Villarreal et al (2000) describe outlier populations; and Lai et al (2010) due to geographical and 
temporal overlap with Tai et al (2017). Genetic studies with geographical overlap were not excluded 
since each study only sampled a small proportion of the target population, so overlap in study 
cohort was deemed unlikely.  
Meta-analysis of epidemiological estimates of prevalence using the inverse variance method with a 
double arcsin transformation gave a pooled prevalence of 1.38 (95% CI: 0.85-2.05) per 100,000 
(Figure 1A). Meanwhile, meta-analysis of mutant allele frequencies estimates from genetic 
sequencing studies gave a pooled allele frequency of 0.011 (95% CI: 0.008-0.015) (Figure 1B). Using 
the Hardy-Weinberg equation, this mutant allele frequency is equivalent to a prevalence at birth of 
12.7 per 100,000 (95% CI: 6.25-23.0). The studies in both meta-analyses showed statistically 
significant heterogeneity (epidemiological: I2= 98.0%, p<0.001; genetic: I2= 76.9%, p<0.001).  
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We then proceeded to attempt to obtain a more reliable estimate of global WD prevalence, using 
publicly available sequencing data.  
 
Identification of ATP7B Variants  
Our systematic search for WD mutations returned 1558 abstracts, of which 245 papers were 
included, from which 771 pathogenic variants were extracted (Figure S2). Screening of the University 
of Alberta WD database and of ClinVar for variants reported as disease-causing in the published 
literature found an additional 10 variants and 1 variant, respectively, giving a total of 782 reported 
disease variants (Figure 2A). GnomAD allele frequency data was available for 238/782 (30.4%) of 
these disease-causing variants. 
A list of all known variants in ATP7B, including non-pathogenic variants and polymorphisms, was also 
compiled. The above reported disease variants were combined with 10,199 variants from Ensembl, 
2,301 from GnomAD, 372 from ClinVar and 654 from the University of Alberta WD database, giving a 
total of 11,520 variants (Figure 2A). The full database can be found at http://www.wilsondisease.tk/ 
and in Table S2. GnomAD allele frequency data was available for 2301/11520 (19.9%) of these 
variants. 
 
Analysis of allele frequencies 
Known pathogenic variants  
Out of 238 reported disease-causing variants with allele frequency data, 234 remained after 
frequency filtering and 216 of these were classified as ‘likely pathogenic’ under ACMG criteria 
(Figure 2A). Pooling of the allele frequencies of these variants gave a global mutant allele frequency 
of 0.0118, which is equivalent to a prevalence at birth of 13.9 per 100,000 (95% CI: 12.9-14.9), or 1 
per 7,194 (Figure 2B and Table S1).  The East Asian ethnicity had the highest estimated prevalence of 
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29.5 per 100,000 (95% CI: 23.6-36.8) compared to only 2.08 per 100,000 (95% CI: 1.43-3.03) in the 
Finnish population. There was insufficient variant-level penetrance data to adjust our estimate based 
on the cumulative penetrance of disease variants. 
The most common mutation consequence was missense, accounting for 52% of all ‘likely 
pathogenic’ variants (including those without allele frequency data) and contributing 85% of the 
total mutant allele frequency (Figure 2C). After that, frameshift and stop gained/lost were the next 
most common.  
50% of the total allele frequency was accounted for by the 9 most frequent variants, the top 5 of 
which are listed in Table 3. p.His1069Gln, the most frequently previously reported variant in the 
European population, ranks 3rd amongst these.  
Predicted pathogenic variants 
In order to estimate the true genetic prevalence of WD, including pathogenic variants that have not 
yet been identified in patients, we examined all variants reported in humans that caused major 
functional or structural changes (frameshift, premature stop codon, splice donor and splice acceptor 
variants). After frequency filtering, 113/11520 (0.98%) variants met these criteria and were found in 
the GnomAD dataset. Of these, 60 had not been previously identified in WD patients. When 
combined with the reported pathogenic variants above, the global mutant allele frequency of WD 
was 0.0124, equating to a birth prevalence of 15.4 per 100,000 (95% CI: 14.4-16.5), or 1 per 6,494 
(Figure 2B and Table S1). The east Asian population had the highest prevalence of 29.7 per 100,000 
(95% CI: 23.8-37.0) and the Finnish population had the lowest prevalence at 2.37 per 100,000 (95% 
CI 1.7-3.4).  
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DISCUSSION 
In this study, we have produced an unbiased description of the genetic prevalence of Wilson disease, 
both globally and across 7 major ethnicities, and this was found to be higher than previous 
estimates. In addition, we have collated a publicly available, up-to-date database of ATP7B gene 
variants with robust classifications of pathogenicity. 
Previous estimates of WD prevalence are extremely heterogeneous, which may be accounted for by 
differences in population, diagnosis and methodology. In particular, it should be remembered that 
the prevalence of WD in isolated populations, such as the Canary Islands and Crete, may be over 35 
per 100,000. In contrast, using the large and diverse sample represented by the GnomAD dataset 
(comprising 123,136 exome sequences and 15,496 whole-genome sequences), we deduce that the 
global genetic prevalence of WD at birth is approximately 13.9 to 15.4 per 100,000. We have 
highlighted that patients of East Asian origin are at the greatest risk of WD, whereas those of Finnish 
origin have the lowest genetic prevalence. 
In particular, our estimate of 13.9 per 100,000, derived from known pathogenic variants, is very 
similar to the prevalence from the meta-analysis of genetic studies (12.7 per 100,000), but both of 
these estimates are significantly higher than the prevalence from the meta-analysis of 
epidemiological studies (1.38 per 100,000). There are several possible reasons for this disparity. 
Firstly, the genetic prevalence calculated in this study does not account for the incomplete 
penetrance of variants, as penetrance data are lacking. If the difference between epidemiological 
(1.4 per 100,000) and genetic (13.9 per 100,000) estimates were due to incomplete penetrance 
alone then the overall disease penetrance would be 10%. However, the genetic studies contributing 
to the meta-analysis were mostly based on a maximum of 6 common pathogenic variants, with the 
exception of Coffey et al. (2013)3 and Gialluisi et al. (2012)17. Since these are mostly well-reported 
variants, which have repeatedly been screened for in control populations, it is unlikely that any of 
12 
these could have a penetrance low enough to account for the extent of disparity between genetic 
and epidemiological estimates. 
Methodological differences may also contribute. WD commonly presents during the second and 
third decades of life, whereas the genotype is present from birth. Thus, the clinical phenotype 
quantified by epidemiological studies only exists for about 80% of an average 70 year lifespan.  
Finally, this disparity may be evidence of under-diagnosis of WD on a population level, as has been 
repeatedly previously suggested3,7, or of delayed diagnosis and consequent early deaths. With good 
compliance, the treatment for WD is highly effective and diagnostic failure has been reported to be 
the principal cause of death in WD patients18. Under-diagnosis may be due to milder disease 
phenotypes, or single-organ system phenotypes, or application of diagnostic criteria recently 
recognized as inappropriately narrow1.  
Thus, we have demonstrated the power and potential limitations of using rapidly expanding genomic 
databases such as GnomAD to estimate the prevalence of recessive diseases. These conclusions are, 
however, limited by the assumptions of the Hardy-Weinberg equation and many of the 
consequence-predicted variants are not yet supported by in vitro data. Moreover, pathogenic 
classification of our previously reported variants is reliant upon accurate diagnosis by the papers we 
screened.  
We also implemented the method for filtering variants by frequency proposed by Whiffin et al 
(2017). As the authors note, a limitation of this procedure is the difficulty in obtaining reliable 
estimates of penetrance and maximum allelic contribution. Therefore, an upper bound for the 
maximum credible allele frequency was used here to avoid filtering out potentially pathogenic 
variants. Although not optimal, such a method is still more stringent than the standard practice of 
discarding variants more frequent than the arbitrary MAF of 5%. It should also be noted that the use 
of frequency filtering was only intended to remove variants too common to realistically be 
pathogenic, rather than to define pathogenic variants. Indeed, only 4 variants were filtered out here 
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and were we to assume 100% penetrance in this formula, only one additional variant would be 
filtered, giving a prevalence estimate of 11.6 per 100,000.  
Our finding of 782 reported disease variants and 60 predicted pathogenic variants associated with 
WD is an update on previous lists of variants and highlights the mutational spectrum of the disease. 
The most common pathogenic variants are missense mutations (accounting for 85% of the 
prevalence), but large deletions and insertions have also been reported. This should be considered in 
efforts to develop an effective screening programme or in targeted genetic testing for the disease.  
In summary, the genetic prevalence of WD is much higher than epidemiological estimates, 
potentially indicating underdiagnosis or the existence of less severe phenotypes. We have also 
produced more reliable global and ethnicity-specific estimates for WD genetic prevalence and in the 
process, a new up-to-date database of WD variants. These results provide important baseline data 
for clinical use, genetic counselling, and informing future research in ATP7B. 
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FIGURE LEGENDS 
Figure 1: Forest plots of previous studies of WD prevalence 
A:Prevalence estimates derived from epidemiological studies 
B:Mutant allele frequencies derived from genetic studies  
Error bars represent 95% CIs. Overall estimates are calculated using random effects models 
PREV = prevalence, MAF = mutant allele frequency, LCL = lower 95% confidence interval, UCL = 
upper 95% confidence interval, WGHT=weight 
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Figure 2: ATP7B gene variants and GnomAD allele frequencies  
A: Identification and classification of ATP7B disease variants  
ATP7B variants were compiled into a new, comprehensive, publicly-available database. Additionally, 
these were filtered in order to obtain estimates of the prevalence of WD. 
i) Reported disease variants were identified by a systematic search of the literature and cross-
referencing with existing databases. Variants found in the GnomAD dataset were then filtered by 
frequency and ACMG criteria to give ‘known disease variants’. 
ii) Reported disease variants and variants from existing databases were combined to give a list of all 
known ATP7B variants. Those found in the GnomAD dataset were filtered by frequency and 
mutation consequence – variants causing major functional or structural changes (frameshift, 
premature stop codon, splice donor and splice acceptor variants) were classified as ‘predicted 
disease variants’. 
n = number of variants, Δnt = nucleotide change. UoA = University of Alberta, AF = allele frequencies 
B: WD disease prevalence estimated from GnomAD allele frequencies 
Estimates of WD prevalence for 7 ethnicities were calculated using the GnomAD allele frequencies of 
known and predicted disease variants (identified as per A). For comparison, estimates of prevalence 
from the meta-analyses of epidemiological and genetic studies are shown by the red and the yellow 
dotted lines, respectively. Error bars represent 95% CIs calculated using the Wilson score method 
C: Mutation consequences of ‘known disease variants’ 
i) Pie chart of the number of variants resulting in each mutation consequence  
ii) Pie chart of the proportion of the total mutant allele frequency accounted for by each mutation 
consequence. del = deletion; ins = insertion; UTR = untranslated region  
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Table 1: Epidemiological studies estimating WD prevalence 
Paper Location Age Range  Year Population size 
(1000s) 
Prevalence (per 
100000) 
AXIS asssessment  
Poujois et al, 201719 France All 2013 58000 1.50 High quality, very low RoB 
Tai et al, 201720 Taiwan All 2000-2011 231621 1.81 High quality, very low RoB 
Lai et al, 2010* 21 Taiwan All 2005 22770 1.60 High quality, very low RoB 
Cheng et al, 201422 Anhui, China 7-75  2008-2011 2700 5.87 Medium quality, risk of sampling bias 
Moller et al, 201123 Denmark All 1990-2008 5494 2.02 High quality, very low RoB 
Giagheddu et al 198524 Sardinia All Unclear 74 2.77 High quality, low RoB 
Adhami et al, 199525 Albania All ?-1991 3267 0.68 Low quality, unclear RoB, unclear methods  
Reilly et al, 199326 Ireland All 1986 35412 0.54 High quality, low RoB 
Park et al, 19916 Scotland All 1989 5091 0.40 High quality, low RoB 
Bonne-Tamir et al, 
199027 
Israel All 1958-1985 4106 0.253 High quality, low RoB 
Garcia-Villarreal et al, 
2000*28 
NE Canary 
Islands, Spain 
All 1981 1586 38.50 Medium quality, risk of non-responder bias 
Dedoussis et al 2005*29 Cretan village All 1978-? Unclear 6666.67 High quality, low RoB 
AXIS = Appraisal tool for Cross-sectional studies10, * = excluded from further analysis 
1 Source: www.ndc.gov.tw, accessed 14/3; 2 www.cso.ie, accessed 14/3, 3Estimated from number of cases an study population detailed in paper  
Tables
2 
Table 2: Genetic studies estimating WD prevalence at birth 
Paper Method Location Sample size Birth Prevalence 
(per 100000) 
AXIS asssessment  
Jang et al, 20177 DNA analysis of neonatal DBSs for 6 mutations  Korea 14835 13.23 High quality, very low RoB 
Jang et al, 20177 Retrospective review of sequencing data for any WD 
disease variant 
Korea 1090 9.22 High quality, very low RoB 
Kim at al, 200830 DNA analysis of neonatal DBSs for 3 mutations  Korea 476 3.05 High quality, very low RoB 
Coffey et al, 20133 DNA analysis of neonatal DBSs for any WD disease 
variant 
UK 1000 14.23 High quality, very low RoB 
Zappu et al, 200831 DNA analysis of neonates for 2 mutations  Kalymnos, Greece 397 13.50 High quality, very low RoB 
Zappu et al, 200831 DNA analysis of neonates for 1 mutation Sardinia  5290 35.75 High quality, very low RoB 
Gialluisi et al, 201217 Homozygosity index approach  Sardinia 178 36.60 High quality, very low RoB 
Mak et al, 200832 DNA analysis of healthy controls for 2 mutations  Hong Kong 660 18.52 High quality, low RoB 
Krumina et al, 200815 DNA analysis of healthy controls for 1 mutation  Latvia 157 3.91 High quality, low RoB 
Olivarez et al, 20018 DNA analysis of neonates for 1 mutation New York state, US 2456 1.82 High quality, very low RoB 
Jang et al, 2017 and Zappu et al, 2008 are represented twice as they each report two separate estimates based on different populations  
AXIS = Appraisal tool for Cross-sectional studies10; DBS = Dried blood spot  
3 
Table 3: Characteristics of the five most frequent ‘known disease variants’ 
Genomic 
location 
cDNA change Protein change SIFT PolyPhen GnomAD AF References 
51946372 c.2972C>T p.Thr991Met deleterious (0) probably_damaging (0.999) 0.00126 33,34 
51935019 c.4135C>T p.Pro1379Ser deleterious (0) probably_damaging (0.978) 0.00106 33 
51944145 c.3207C>A p.His1069Gln deleterious (0) probably_damaging (1) 0.00101 35–37 etc  
51950132 c.2605G>A p.Gly869Arg deleterious (0) probably_damaging (0.996) 0.00072 28,34,38 etc  
51961849 c.1934T>G p.Met645Arg tolerated (0.42) benign (0) 0.00048 38–40 etc 
 
 
 
 
SUPPLEMENTARY DATA 
 
Supplementary Figure 1: PRISMA flow chart for the selection of relevant papers estimating prevalence of WD 
(n = number of papers) 
 
 
Supplementary Figure 2: Pathway for identification of relevant WD mutation papers (n = number of papers) 
Supplementary data 1
  
Supplementary Figure 3: AXIS tool assessment of study quality and RoB 
Proportion of studies classified as low, unclear and high quality for each of the sections of the AXIS assessment 
Supplementary table 1 -  WD disease prevalence estimated from GnomAD allele frequencies 
 PREVALENCE (per 100,000) 
 All African / 
American 
American Ashkenazi 
Jewish 
East Asian Finnish Non-Finnish 
European 
South Asian Other 
combined 
Known DV 13.9 
(12.9-14.9) 
2.0 
(1.4-3.0) 
11.3 
(9.1-14.0) 
21.9 
(15.9-30.0) 
29.5 
(23.6-36.8) 
2.1 
(1.4-3.0) 
20.7 
(18.9-22.7) 
10.5 
(8.5-13.1) 
8.1 
(4.8-13.6) 
Known + 
Predicted DV  
15.4 
(14.4-16.5) 
3.2 
(2.2-4.6) 
11.7 
(9.5-14.5) 
21.9 
(15.9-30.0) 
29.7 
(23.8-37.0) 
2.4 
(1.7-3.4) 
23.0 
(21.0-25.2) 
11.2 
(9.0—13.9) 
11.2 
(6.8-18.4) 
Estimates of WD prevalence for 7 ethnicities were calculated using the GnomAD allele frequencies of known and predicted disease variants (identified as per Figure 2). 95% 
Confidence intervals are shown in brackets  
DV = disease variants 
 
  
Search terms  
Prevalence search 
Full MEDLINE search term: 
("Wilson Disease" OR "Wilson's Disease" OR ATP7B OR wilson disease[MeSH Terms]) AND (prevalence OR epidemiology OR occurrence OR distribution OR frequency 
OR prevalence[MeSH Terms] OR epidemiology [MeSH Terms]) NOT review[publication type]  
Full EMBASE search term: 
("Wilson Disease" OR "Wilson's Disease" OR ATP7B) AND (prevalence OR epidemiology OR occurrence OR distribution OR frequency) 
Limit to (human and english language and exclude medline journals and articles) 
 
Mutations search  
Full MEDLINE search term:  
("Wilson Disease" OR "Wilson's Disease" OR ATP7B OR wilson disease[MeSH Terms])  
AND (mutation OR variant OR genetics OR mutation [MeSH Terms])  
NOT review[publication type]  
Full EMBASE search term: 
("Wilson Disease" OR "Wilson's Disease" OR ATP7B) AND (mutation OR variant OR genetics) 
limit to (human and english language and exclude medline journals and article) 
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